Seres Therapeutics, Inc.

NasdaqGS:MCRB 주식 보고서

시가총액: US$167.3m

Seres Therapeutics 관리

관리 기준 확인 3/4

Seres Therapeutics CEO는 Eric Shaff, Jan2019 에 임명되었습니다 의 임기는 5.83 년입니다. 총 연간 보상은 $ 3.16M, 21.7% 로 구성됩니다. 21.7% 급여 및 78.3% 보너스(회사 주식 및 옵션 포함). 는 $ 166.99K 가치에 해당하는 회사 주식의 0.1% 직접 소유합니다. 166.99K. 경영진과 이사회의 평균 재임 기간은 각각 5.2 년과 8.2 년입니다.

주요 정보

Eric Shaff

최고 경영자

US$3.2m

총 보상

CEO 급여 비율21.7%
CEO 임기5.8yrs
CEO 소유권0.1%
경영진 평균 재임 기간5.2yrs
이사회 평균 재임 기간8.2yrs

최근 관리 업데이트

Recent updates

Little Excitement Around Seres Therapeutics, Inc.'s (NASDAQ:MCRB) Revenues As Shares Take 30% Pounding

Nov 15
Little Excitement Around Seres Therapeutics, Inc.'s (NASDAQ:MCRB) Revenues As Shares Take 30% Pounding

Seres Therapeutics' Strategic Sale Of Vowst Warrants A Rating Upgrade

Sep 23

Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 44% But Investors Aren't Buying For Growth

Jul 13
Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 44% But Investors Aren't Buying For Growth

Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 46% But Investors Aren't Buying For Growth

May 08
Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 46% But Investors Aren't Buying For Growth

Benign Growth For Seres Therapeutics, Inc. (NASDAQ:MCRB) Underpins Stock's 30% Plummet

Mar 23
Benign Growth For Seres Therapeutics, Inc. (NASDAQ:MCRB) Underpins Stock's 30% Plummet

Seres Therapeutics' Balancing Act: Breakthrough IP And Financing Concerns

Jan 30

Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 30% Price Drop

Dec 18
Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 30% Price Drop

Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 27% Price Drop

Aug 31
Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 27% Price Drop

Seres Therapeutics (NASDAQ:MCRB) Has Debt But No Earnings; Should You Worry?

Aug 09
Seres Therapeutics (NASDAQ:MCRB) Has Debt But No Earnings; Should You Worry?

Is Seres Therapeutics (NASDAQ:MCRB) Weighed On By Its Debt Load?

Dec 28
Is Seres Therapeutics (NASDAQ:MCRB) Weighed On By Its Debt Load?

Estimating The Fair Value Of Seres Therapeutics, Inc. (NASDAQ:MCRB)

Sep 01
Estimating The Fair Value Of Seres Therapeutics, Inc. (NASDAQ:MCRB)

Seres Therapeutics: What The Market Is Missing

Aug 19

Seres Therapeutics GAAP EPS of -$0.70 misses by $0.10, revenue of $1.22M

Aug 03

Seres Therapeutics: The Good And The Challenging

Jul 12

Seres Therapeutics stock slips on $100M stock offering

Jun 30

Is Seres Therapeutics (NASDAQ:MCRB) Using Too Much Debt?

Jun 16
Is Seres Therapeutics (NASDAQ:MCRB) Using Too Much Debt?

Seres Therapeutics: As Biotech Fades The Case For Seres Investment Strengthens

Jun 09

Seres Therapeutics Is Playing A Long Game

Mar 06

Some Seres Therapeutics, Inc. (NASDAQ:MCRB) Analysts Just Made A Major Cut To Next Year's Estimates

Mar 02
Some Seres Therapeutics, Inc. (NASDAQ:MCRB) Analysts Just Made A Major Cut To Next Year's Estimates

Rock star Growth Puts Seres Therapeutics (NASDAQ:MCRB) In A Position To Use Debt

Dec 27
Rock star Growth Puts Seres Therapeutics (NASDAQ:MCRB) In A Position To Use Debt

CEO 보상 분석

Eric Shaff 의 보수는 Seres Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Sep 30 2024n/an/a

-US$68m

Jun 30 2024n/an/a

-US$162m

Mar 31 2024n/an/a

-US$83m

Dec 31 2023US$3mUS$685k

-US$114m

Sep 30 2023n/an/a

-US$224m

Jun 30 2023n/an/a

-US$153m

Mar 31 2023n/an/a

-US$265m

Dec 31 2022US$4mUS$662k

-US$250m

Sep 30 2022n/an/a

-US$231m

Jun 30 2022n/an/a

-US$103m

Mar 31 2022n/an/a

-US$87m

Dec 31 2021US$10mUS$625k

-US$66m

Sep 30 2021n/an/a

-US$34m

Jun 30 2021n/an/a

-US$132m

Mar 31 2021n/an/a

-US$105m

Dec 31 2020US$3mUS$590k

-US$89m

Sep 30 2020n/an/a

-US$90m

Jun 30 2020n/an/a

-US$76m

Mar 31 2020n/an/a

-US$66m

Dec 31 2019US$2mUS$540k

-US$70m

Sep 30 2019n/an/a

-US$73m

Jun 30 2019n/an/a

-US$78m

Mar 31 2019n/an/a

-US$95m

Dec 31 2018US$1mUS$435k

-US$99m

Sep 30 2018n/an/a

-US$107m

Jun 30 2018n/an/a

-US$92m

Mar 31 2018n/an/a

-US$92m

Dec 31 2017US$2mUS$377k

-US$89m

보상 대 시장: Eric 의 총 보상 ($USD 3.16M )은 US 시장( $USD 1.45M ).

보상과 수익: Eric 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Eric Shaff (48 yo)

5.8yrs

테뉴어

US$3,158,336

보상

Mr. Eric D. Shaff, M.B.A., serves as President and Chief Executive Officer at Seres Therapeutics, Inc. since January 15, 2019 and serves as its Director since January 2019. He served as Chief Operating Off...

리더십 팀

이름위치테뉴어보상소유권
Eric Shaff
President5.8yrsUS$3.16m0.10%
$ 167.0k
Lisa von Moltke
Executive VP & Chief Medical Officer4.7yrsUS$1.57m0.019%
$ 31.8k
Teresa Young
Executive VP and Chief Commercial & Strategy Officer4.4yrsUS$1.82m0.053%
$ 88.6k
Marella Thorell
Executive VP & CFOless than a year데이터 없음데이터 없음
David Ege
Executive VP & Chief Technology Officer4.1yrsUS$5.32m0.045%
$ 76.0k
Matthew Henn
Executive VP & Chief Scientific Officer5.8yrsUS$1.67m0.046%
$ 76.2k
Carlo Tanzi
Investor Relations Officer9yrs데이터 없음데이터 없음
Thomas DesRosier
Chief Legal Officer8.5yrsUS$1.44m0.079%
$ 132.5k
Caroline Holda
Assistant General Counselno data데이터 없음데이터 없음

5.2yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 관리: MCRB 의 관리팀은 노련하고 경험 (평균 재직 기간 5.2 년)입니다.

이사회 구성원

이름위치테뉴어보상소유권
Eric Shaff
President5.8yrsUS$3.16m0.10%
$ 167.0k
Willard Dere
Independent Director7.3yrsUS$225.23k0.019%
$ 31.1k
Dennis Ausiello
Independent Director9.6yrsUS$222.27k0%
$ 0
Kurt Graves
Independent Director9yrsUS$219.23k0%
$ 0
Richard Kender
Independent Director10.1yrsUS$232.69k0.037%
$ 62.2k
Mark Wilcox
Member of Scientific Advisory Board9.8yrs데이터 없음데이터 없음
Andrew Goodman
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Curtis Huttenhower
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Paul Biondi
Independent Director4.7yrsUS$211.73k0.028%
$ 46.7k
Stephen Berenson
Independent Chairman5.3yrsUS$249.23k0.0021%
$ 3.5k
Robert Jenq
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Elhanan Borenstein
Member of Scientific Advisory Boardno data데이터 없음데이터 없음

8.2yrs

평균 재임 기간

63yo

평균 연령

경험이 풍부한 이사회: MCRB 의 이사회는 경험(평균 재직 기간 8.2 년)으로 간주됩니다.